drugset / Trial / NCT05209308
Rituximab Plus Venetoclax in Combination With Zandelisib in Subjects With CLL
Non-randomizedSequentialOpen-labelTreatment
Summary
A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.
Timeline
- Start
- 2022-11-22
- Primary completion
- 2023-03-15
- Completion
- 2023-03-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Venetoclax | Small molecule | — | Oral |
| Subject | Zandelisib | Small molecule | — | Oral |
| Background | Rituximab | Monoclonal antibody | — | Intravenous |